Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Oncologic outcome and safety profile of first-line enfortumab vedotin plus pembrolizumab vs. conventional chemotherapy in advanced urothelial cancer.

Exploration of targeted anti-tumor therapy·2026

Same author

Blood Pressure Changes After Oral 5-Aminolevulinic Acid Hydrochloride Administered 4-8 h Before TURBT: An Additional Analysis of a Phase III Study (SPP2C102).

Life (Basel, Switzerland)·2026

Same author

Phylogenetic Analyses of <i>RdRp</i> Region and <i>VP1</i> Gene in Human Norovirus Genotype GII.17[P17] Variants.

Microorganisms·2026

Same author

Decoding viral evolution through integrative bioinformatics: From genomes to global health.

Virology·2026

Same author

Changes of urinary immunity and microbiome after intravesical BCG therapy and their association with outcomes in NMIBC.

Exploration of targeted anti-tumor therapy·2026

Same author

ASO Visual Abstract: Fluorescent Ureterorenoscopy-Assisted Thulium:YAG and Holmium:YAG Dual Laser Ablation for Upper Urinary Tract Urothelial Carcinoma: Results of the FLUAM Trial.

Annals of surgical oncology·2026

Search research articles

Related Experiment Video

Updated: Feb 28, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Clinical Outcomes of Hypofractionated Radiotherapy With 12 Fraction for Low- and Intermediate-Risk Localized Prostate

Kota Iida¹, Yuriko Hayashi¹, Kosuke Narita¹

¹Department of Urology, Tane General Hospital, Osaka, Japan.

International Journal of Urology : Official Journal of the Japanese Urological Association

|February 27, 2026

Summary

Hypofractionated radiotherapy offers similar cancer control to conventional treatment for low- to intermediate-risk prostate cancer. This approach shows an acceptable toxicity profile, making it a viable alternative for patients.

Keywords:

adverse events biochemical recurrence conventional fractionation hypofractionated radiotherapy localized prostate cancer

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Feb 28, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Area of Science:

Oncology
Radiation Oncology
Urology

Background:

Hypofractionated radiotherapy is gaining traction for prostate cancer treatment.
Evidence supports the clinical use of hypofractionation in managing prostate cancer.

Purpose of the Study:

To compare oncological outcomes and toxicity between hypofractionated and conventional radiotherapy for prostate cancer.
To evaluate the efficacy and safety of hypofractionated radiotherapy in a real-world setting.

Main Methods:

Retrospective study including 96 patients with low- to intermediate-risk prostate cancer.
Comparison between conventional radiotherapy (78.0 Gy/39 fractions) and hypofractionated radiotherapy (51.6 Gy/12 fractions).
Assessment of survival outcomes and acute/late toxicities (urinary and bowel).

Main Results:

Comparable oncological outcomes with only one biochemical recurrence in the conventional group.
No significant difference in acute grade ≥2 urinary or bowel toxicity.
Trends towards higher late urinary toxicity in the hypofractionated group and late bowel toxicity in the conventional group, without statistical significance.

Conclusions:

Hypofractionated radiotherapy is a safe and effective alternative for low- to intermediate-risk prostate cancer.
It demonstrates comparable oncological control and an acceptable toxicity profile to conventional fractionation.
Supports the broader adoption of hypofractionation in prostate cancer management.